1-3 of 3
K. Michael Weidner, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Differential Patterns of Gene Expression and CD20 Localisation by the Type II Anti-CD20 Antibody Obinutuzumab (GA101) Compared with the Type I Antibody Rituximab Suggests Binding to Functionally Distinct CD20 Subpopulations on B-Cell Lymphoma Cell Lines,

Gerhard Niederfellner, Olaf Mundigl, Alexander Lifke, Andreas Franke, Ute Baer, Helmut Burtscher, Daniela Maisel, Anton Belousov, K. Michael Weidner, PhD, Pablo Umana, PhD, Christian Klein, PhD
Journal: Blood
Blood (2011) 118 (21): 3721.
https://doi.org/10.1182/blood.V118.21.3721.3721
Published: 2011
Journal Articles

Superior Efficacy of the Novel Type II, Glycoengineered CD20 Antibody GA101 vs . the Type I CD20 Antibodies Rituximab and Ofatumumab

Sylvia Herter, Inja Waldhauer, Tina Otz, Frank Herting, Sabine Lang, Valeria Nicolini, Michaela Römmele, Thomas Friess, Erwin Van Puijenbroek, Marina Bacac, K. Michael Weidner, PhD, Christian Gerdes, Pablo Umana, PhD, Christian Klein, PhD
Journal: Blood
Blood (2010) 116 (21): 3925.
https://doi.org/10.1182/blood.V116.21.3925.3925
Published: 2010
Journal Articles

Anti-Angiogenic Activity of a Tetravalent Bispecific Antibody (TAvi6) Targeting VEGF and Angiopoietin-2

K. Michael Weidner, PhD, Werner Scheuer, PhD, Markus Thomas, PhD, Monika Baehner, PhD, Stefan Seeber, PhD, Hubert Kettenberger, PhD, Juergen Schanzer, PhD, Ulrich Brinkmann, PhD, Joerg T. Regula, Christian Klein, PhD
Journal: Blood
Blood (2010) 116 (21): 4304.
https://doi.org/10.1182/blood.V116.21.4304.4304
Published: 2010